ArticleLeukemia research reports2022

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax.

Soon Khai Low et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.